Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,297.03
    +40.63 (+0.05%)
     

  • CMC Crypto 200

    1,382.36
    +69.74 (+5.31%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Arthritis Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

ReportLinker
·3 min read

Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc. , Amgen Inc. , Genentech, GSK, AstraZeneca PLC, and Mylan N. V. The global arthritis monoclonal antibodies market is expected to grow from $44.

New York, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Arthritis Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030" - https://www.reportlinker.com/p06151675/?utm_source=GNW
82 billion in 2020 to $48.08 billion in 2021 at a compound annual growth rate (CAGR) of 7.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $62.29 billion in 2025 at a CAGR of 7%.

The arthritis monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of arthritis diseases.Arthritis is referred to as the joint pain that is characterized by inflammation, tenderness, pain and stiffness in and around the joints.

Different monoclonal antibody drugs are used for the treatment of arthritis.These include infliximab, adalimumab and golimumab.

The market consists of revenue generated by the company’s manufacturing monoclonal antibody drugs for arthritis by the sales of these products.

The arthritis monoclonal antibodies market covered in this report is segmented by drug into remicade, humira, enbrel, rituxan, orencia, actemra, simponi, cimzia, remsima and by application into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The high cost of monoclonal antibodies is expected to hamper the global arthritis monoclonal antibody market.According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731.

The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth.

In May 2020, AbbVie acquired Allergan for $63 billion.AbbVie is a global biopharmaceutical company whose key therapeutic areas include Immunology and Neuroscience.

It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, surgical and regenerative medicinal products all across the world.

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market.According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in USA which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia and rheumatoid arthritis.

According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1% and the worldwide estimates of osteoarthritis include 9.6% men and 18% women. The increased prevalence of arthritis and thee demand for personalized medicine is increasing the demand for the arthritis monoclonal antibody market.

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market.Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis.

These are target specific and has good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06151675/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001